Author(s): Kwak EL, Bang YJ, CamidgeDaR, Shaw AT, Solomon B,et al.
Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non–small-cell lung cancers, representing 2 to 7% of such tumors. We explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clinical trial of crizotinib (PF-02341066), an orally available small-molecule inhibitor of the ALK tyrosine kinase.METHODS
After screening tumor samples from approximately 1500 patients with non–small-cell lung cancer for the presence of ALK rearrangements, we identified 82 patients with advanced ALK-positive disease who were eligible for the clinical trial. Most of the patients had received previous treatment. These patients were enrolled in an expanded cohort study instituted after phase 1 dose escalation had established a recommended crizotinib dose of 250 mg twice daily in 28-day cycles. Patients were assessed for adverse events and response to therapy.
Referred From: https://www.nejm.org/doi/full/10.1056/nejmoa1006448
Author(s): Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y,et al.
Author(s): Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M,et al.
Author(s): Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E,et al.
Author(s): Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J,et al.
Author(s): Lee JK, Park HS, Kim DW, Kulig K, Kim TM,et al.